Literature DB >> 24813350

Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.

Z M Younossi1, M Otgonsuren, L Henry, Z Arsalla, M Stepnaova, A Mishra, C Venkatesan, S Hunt.   

Abstract

Although the incidence of new hepatitis C virus (HCV) infection has fallen, HCV-related complications are on the rise. Our aim was to assess and describe the 2005-2009 national inpatient mortality and resource utilization trends for patients with HCV. Data from the National Inpatient Sample (NIS) and the National Hospital Discharge Survey (NHDS) between 2005 and 2009 were analyzed. Included were all adult hospital discharges with HCV-related ICD-9 codes. Incremental hospital charge, in-hospital mortality and length of stay (LOS) were estimated using n = 1000 bootstrap replicates clustered by unique hospital identifier. A total of 123 939 (0.38%) discharges were related to HCV (primary or secondary diagnosis). In-hospital mortality increased from 1.7% (2005) to 2.6% (2009) (P < 0.001). Inflation-adjusted charges increased 2% annually from 2005 ($16 455 ± $570) to 2009 ($17 532 ± $1007, P = 0.029). This increase occurred despite the average LOS (5 days) and hospital costs ($6500) remaining stable while at the same time, hospital-to-hospital transfer admissions and disposition to home health care increased. HCV-related hepatocellular carcinoma predicted longer hospital stay and death; older age predicted death; and receiving more procedures predicted higher hospital costs. The percentage of patients with private insurance significantly decreased (4.7%), while government-sponsored insurance and uninsured increased by 2.5% and 2.1%, respectively (P < 0.05). Uninsured patients had a 49%-72% greater chance of dying during hospitalization than those with government-sponsored insurance. HCV-related inpatient mortality and resource utilization have increased. HCC was the largest predictor for mortality and resource utilization. These data are consistent with the rising clinical and societal burden of chronic hepatitis C in the United States.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  National Inpatient Sample; hepatitis C virus; outcomes

Mesh:

Year:  2014        PMID: 24813350     DOI: 10.1111/jvh.12262

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  13 in total

1.  Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C.

Authors:  George Cholankeril; Ryan B Perumpail; Menghan Hu; Gail Skowron; Zobair M Younossi; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2016-04-15       Impact factor: 3.199

2.  Ten-year trends and prediction model of 30-day inpatient mortality for alcoholic hepatitis in the United States.

Authors:  Hassam Ali; Rahul Pamarthy; Nicole Leigh Bolick; Muhammad Fahd Farooq
Journal:  Ann Gastroenterol       Date:  2022-05-12

3.  The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis.

Authors:  Alysse G Wurcel; Deirdre J Burke; Jianing J Wang; Brian Engle; Kathryn Noonan; Tamsin A Knox; Arthur Y Kim; Benjamin P Linas
Journal:  J Urban Health       Date:  2018-08       Impact factor: 5.801

4.  The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study.

Authors:  Folasade P May; Vineet S Rolston; Elliot B Tapper; Ashwini Lakshmanan; Sammy Saab; Vinay Sundaram
Journal:  BMC Gastroenterol       Date:  2016-10-10       Impact factor: 3.067

5.  The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia.

Authors:  Allister Sebastian Lee; Mieke L van Driel; Darrell Hg Crawford
Journal:  Clinicoecon Outcomes Res       Date:  2017-10-03

6.  Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.

Authors:  Kian Bichoupan; Neeta Tandon; James F Crismale; Joshua Hartman; David Del Bello; Neal Patel; Sweta Chekuri; Alyson Harty; Michel Ng; Keith M Sigel; Meena B Bansal; Priya Grewal; Charissa Y Chang; Jennifer Leong; Gene Y Im; Lawrence U Liu; Joseph A Odin; Nancy Bach; Scott L Friedman; Thomas D Schiano; Ponni V Perumalswami; Douglas T Dieterich; Andrea D Branch
Journal:  World J Virol       Date:  2017-11-12

7.  Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal.

Authors:  Parmvir Parmar; Daniel J Corsi; Curtis Cooper
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-17

8.  Age-standardized mortality rates related to viral hepatitis in Brazil.

Authors:  Hugo Perazzo; Antonio G Pacheco; Paula M Luz; Rodolfo Castro; Chris Hyde; Juliana Fittipaldi; Caroline Rigolon; Sandra W Cardoso; Beatriz Grinsztejn; Valdiléa G Veloso
Journal:  BMC Infect Dis       Date:  2017-07-31       Impact factor: 3.090

9.  Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces.

Authors:  Hai-Yang Zhou; Shuang Liu; Su-Jun Zheng; Xiao-Xia Peng; Yu Chen; Carol Duan; Qing-Fen Zheng; Zhao Wang; Zhong-Ping Duan
Journal:  Hepatol Med Policy       Date:  2016-04-28

10.  Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States.

Authors:  Pegah Golabi; Munkhzul Otgonsuren; Winnie Suen; Aaron B Koenig; Bashir Noor; Zobair M Younossi
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.